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license (http://creativetrating the need for more effective therapeutic targets. Histone deacetylase 6 (HDAC6) modulates
tubulin acetylation and has been implicated as an attractive target. HDAC6 is also elevated in post-
mortem tissue samples from patients. However, HDAC6 inhibitors have had limited success preclini-
cally due to low blood-brain barrier penetration.
Method: We investigated a specific, potent HDAC6 inhibitor (ACY-738) in a mouse model of AD.
We determined the effects of ACY-738 treatment on axonal transport, behavior, and pathology in am-
yloid precursor protein/presenilin 1 mice.
Results: We demonstrated improvements in in vivo axonal transport in two treatment groups as a
result of ACY-738 brain levels. We also demonstrated recovery of short-term learning and memory
deficits, hyperactivity, and modifications of tau and tubulin.
Discussion: Our findings implicate specific, targeted HDAC6 inhibitors as potential therapeutics and
demonstrate that further investigations are warranted into effects of HDAC6 inhibitors in AD.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Alzheimer’s disease (AD) is a progressive, neurodegener-
ative disorder that affected over 5 million people in the United
States alone last year [1]. The prevalence of this disease is
projected to double by the year 2040. Currently, patients
can be diagnosed with probable AD with a combined profile
of positron emission topography imaging, cognitive score,
and genetic analysis. However, a confirmation of the threeuthor. Tel.: 11-713-798-5705; Fax: 11-713-798-
autler@bcm.edu
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).pathologic hallmarks of the disease (amyloid-beta [Ab] pla-
ques, neurofibrillary tau tangles, and neurodegeneration)
cannot be fully assessed unless an autopsy is performed. Cur-
rent Food and Drug Administration-approved therapeutics for
management of the symptoms of this disease primarily
include cholinesterase inhibitors [2]. In addition, drugs that
target two pathologic hallmarks (Ab plaques and neurofibril-
lary tau tangles) of the disease have been explored. Specif-
ically, small molecule inhibitors of Ab aggregation or
production are under development and have hadmixed results
in clinical trials [3]. Inhibitors of tau-induced neurotoxicity
such as inhibitors of kinases (CDK5, GSK3b) have also
been explored with limited success, often due to their lack
of brain bioavailability. These include targeting either theimer’s Association. This is an open access article under the CC BY-NC-ND
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and the formation of filamental tangles [4]. Even more
recently, increased attention has been paid to the biological
role of tau in microtubule stabilization, which is a vital struc-
ture for the health of axons in the brain. Several studies have
investigated the crucial role of axons and their ability to trans-
port organelles and vesicles to and from synapses in neurons
via microtubules [5–7]. In fact, recent studies [8,9] describe
the damage of several components of microtubules in
neurodegenerative disease, specifically with genetic
mutations in common cytoskeletal and motor components
of microtubules [9].
Microtubules are composed mainly of two polymer pro-
teins, a- and b-tubulin [10]. These proteins are regulated
by posttranslational modifications (PTMs) including acety-
lation and phosphorylation. These PTMs can play crucial
roles in the stability, guidance, and transport that take place
along these axons. Because of this, the physiological process
of microtubule-based axonal transport is of great interest as a
functional indicator of neuronal health.
We and others have shown that microtubule-based axonal
transport can be measured directly in vivo in models of AD
using manganese-enhanced magnetic resonance imaging
(MEMRI) [11–15]. Over the past 20 years, this technique
has been used in vivo in rodent models to confirm
in vitro and ex vivo impairments in axonal transport rate
[12–14,16–18]. Thus, the MEMRI technique offers an
in vivo methodology for microtubule-based axonal transport.
Furthermore, microtubule-destabilizing agents (i.e., colchi-
cine) can be used in vivo to confirm blockage of axonal trans-
port using MEMRI. Recent studies have confirmed in vivo
deficits in microtubule-based axonal transport are present
before the onset of tau tangles in tauopathy models [13,16].
These deficits are highly correlated with PTMs of tau.
In addition to tau, tubulin is another key building block
within microtubules that can be acetylated or deacetylated
by histone deacetylase 6 (HDAC6) [19]. Evidence in patient
samples indicates that this regulation is disrupted because of
the level of HDAC6 being elevated in the brains of patients
with AD, specifically by 52% in the cortex and 91% in the
hippocampus, which is the center for learning and memory
[20,21]. In addition, levels of acetylated a-tubulin protein
are decreased in AD patient brains. HDAC6 has also been
shown to interact with tau independent of its deacetylase
activity and also helps to recruit chaperone proteins within
the autophagic process to help clear protein aggregates.
Studies also indicate that HDAC6 can directly modulate
the phosphorylation and acetylation of tau as a protein
[19,21,22]. These functions have been demonstrated in
recent studies in multiple models of AD [21,23–26].
Because of the various functions of HDAC6 in neurons
and its potential as a therapeutic target, a number of inhib-
itors have been developed. The first of these includes tuba-
cin, which is specific to the a-tubulin regulation and to
HDAC6; however, it has high lipophilicity and is difficult
to synthesize [10,27]. The second is tubastatin A and itsrespective group of analogs. This family of drugs is less
lipophilic and more selective for HDAC6 and its
deacetylase activity, but dosing mice with this compound
did not result in significant brain exposure [28]. However,
a recent study compared these two inhibitors and did find
that tubastatin A was most effective in the peripheral ner-
vous system at rescuing distal axonal loss andmuscle inner-
vation in mouse models of Charcot-Marie-Tooth disease
[29]. Most recently, Acetylon Pharmaceuticals has devel-
oped a series of selective and potent HDAC6 inhibitors
that efficiently cross the blood-brain barrier. In a recent
study, one of the compounds in this series, ACY-738, re-
sulted in an antidepressant-like phenotype in a social
defeat model of depression in mice. Thus, we sought to
evaluate the effectiveness of ACY-738 in an amyloid mouse
model of AD on axonal transport, behavior, and amyloid
pathology.
Specifically, we chose the amyloid precursor protein/
presenilin 1 (APP/PS1) mouse model because of the rele-
vance of increased amyloid as an early marker of cognitive
impairment in patients and in mice. In addition, amyloid
has been highly associated with impairments in axonal
transport and microtubule instability. Reduced axonal
transport has been correlated with poor behavioral out-
comes in mouse models of AD [8,12,30]. These
correlations have linked Aß with tau proteins within
dystrophic axons, leading to deficits in axonal transport.
In addition, axonal transport deficits have been
implicated as triggers for increased oxidative stress, and
can lead to higher Aß deposition over time. Many of the
proteins involved with this processing, including APP and
PS1 have been observed to be accumulated in axons at
presynaptic terminals, indicating that this transport
process is necessary in the delivery of these cargo
[31,32]. Specifically, the process of fast anterograde
axonal transport is responsible for the delivery of these
proteins. In addition, evidence suggests that APP directly
interacts with kinesin in the development of microtubules
and promotes axonal growth. Additional in vitro evidence
of APP and PS1 manipulation in cell culture leads to
altered axonal growth, morphologic changes, and
swelling within neurons [33,34]. Finally, the APP/PS1
mouse model has been characterized using the MEMRI
methodology for measurements of noninvasive, in vivo
axonal transport rates, with rates decreasing beginning at
age 3 months before overt biochemical changes in
pathology as well as learning and memory deficits. Thus,
we chose to evaluate the effects of ACY-738 at this time
point, referred as 21 day or early treatment throughout
the article. We selected a longer, 90-day treatment begin-
ning at 3 months and evaluated at 6 months, referred to
as the late or 90-day treatment throughout the article.
Finally, axonal transport deficits have been linked to oxida-
tive stress abnormalities before the onset of plaque deposi-
tions, all of which affect the microtubule network which
ACY-738 targets through HDAC6 inhibition.
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2.1. Animal model and genotyping
APP/PS1 mice that overexpress both the APP and PS1
with a deletion in exon 9 have been described previously
[35]. The transgenic mice were gifts from Hui Zheng (Bay-
lor College of Medicine), and male breeders were crossed
with wild-type (WT) C57/Bl6J females from Jackson Lab-
oratories. For all groups, both male and female mice were
used, and pilot studies were conducted before data collec-
tion to confirm no sex differences in these measurements.
Mouse genotypes were determined from tail tissue from
mice using real-time quantitative polymerase chain reac-
tion with specific probes for the PSEN1 gene by a commer-
cial provider. To perform the genotyping, tissues from mice
were digested in extraction buffer (components of buffer) at
75C for 5 minutes and vortexed. They were then digested
for 10 minutes at 95C before DNAwas extracted. Polymer-
ase chain reaction cycling conditions were as follows: 95C
for 3 minutes, 95C for 15 seconds, 62C for 15 seconds,
72C for 20 seconds, and 95C for 3 minutes for 34 cycles.
Animal housing and use were in compliance with the Na-
tional Institutes of Health guidelines for the Care and Use
of Laboratory Animals and were approved by the Institu-
tional Animal Care and Use Committee at Baylor College
of Medicine.2.2. Contextual fear conditioning
Contextual fear conditioning tests were conducted in the
same manner as previously described [36]. Briefly, mice
were first habituated for 30 minutes in the behavioral suite
and then placed in fear conditioning chambers. A training
protocol was administered using Freeze Frame software
(Coulbourn Instruments), which consists of two instances
of a low tone paired with a mild electric foot shock
(0.7 mA) in a 3-minute time frame. The amount of time
that the mice were immobile, designated as “freezing” in
this protocol was recorded by the software. For short-term
recall, mice were placed back in the same chamber without
a tone or foot shock, to measure contextual fear conditioning
2 hours after testing. For long-term recall, mice were again
placed in the same chamber 24 hours after testing. Both out-
puts were measured using Freeze View software (Coulbourn
Instruments) after individually adjusting a baseline freezing
threshold for each mouse that was tested.2.3. Manganese administration
Mice were anesthetized with 5% isoflurane in 100% O2
for 2 minutes to administer a nasal lavage of 4 mL of 0.75-
g/mL MnCl2 dissolved in nanopure water. Once this was
administered, the animals were placed back into their cage
and allowed to recover. One hour after lavage administra-
tion, the mice were exposed to 5% isoflurane and then care-
fully exposed to 2% isoflurane in 100% O2 for imaging.Mice were then placed in a head holder while respiratory
rate was monitored and temperature was maintained at
37C. This was done using an air heating system with the
Model 1025 Small Animal Monitoring and Gating System
Software (SA Instruments, Inc).
2.4. Magnetic resonance imaging
All images in this study were acquired with a 9.4-T
Bruker Avance BioSpec spectrometer, 21-cm bore horizon-
tal scanner with a 35-mm volume resonator (Bruker Bio-
Spin, Billerica, MA, USA). Imaging parameters of the
olfactory MEMRI scans were as follows: echo
time 5 8.536 ms, relaxation time 5 504 ms, field of
view 5 30 mm2, slice thickness 5 1 mm, matrix 5 128
! 128, number of excitations 5 2, and number of
cycles 5 15 (each cycle taking about 2 minutes) to acquire
using ParaVision software (Bruker BioSpin). The scan was
a RARE sequence scan that was modified to have six slices
per cycle. The first slice was consistently aligned at the most
posterior point of the olfactory bulb to ensure slice reproduc-
ibility from mouse to mouse for the MEMRI scans.
2.5. Magnetic resonance imaging data analysis
All scans were analyzed using ParaVision software
(Bruker BioSpin). The length of the olfactory bulb was
measured and a line was placed on the image. From the
midpoint of this line, a 90 angle was drawn, extending out-
ward toward the olfactory neuronal layer (ONL), where the
region of interest (ROI) was selected. Signal intensity was
measured in a ROI of one pixel in the ONL on the right
side of the olfactory bulb because of a chemical shift artifact
present on the left side of the bulb [12,37]. One pixel was
selected because of the pixel representing one fascicle of
axons that project into the ONL. Single glomeruli are the
target of these fascicles and one pixel minimizes outside
variation from other fascicles within the olfactory
epithelium [38]. Another ROI of nine pixels was used to
measure signal intensity in the water phantom. All ONL
ROIs were normalized to water phantom ROIs for 15 mea-
surements, which correspond to the 15 cycles in the scan
to account for any differences in intensities from experi-
ment to experiment. This normalized signal intensity was
used to plot 15 measurements per mouse. The slope of this
line was then established as the axonal transport rate for
each mouse. For statistical analysis, two-tailed Student t
tests was used to test for differences between WT and
APP/PS1 mice with each set of axonal transport measure-
ments (early and late cohorts).
2.6. Serum processing
Mice were briefly anesthetized before performing a retro-
orbital bleed. Blood was collected from 6-month-old mice
(late cohort) using heparinized coated tubes (Fisher). Plasma
was isolated by centrifuging blood samples at 7800 rpm for
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ice and stored at 280C until use.
2.6.1. Brain tissue processing
Mice were sacrificed at ages 3 and 6 months for the early
and late cohorts, respectively. The brain was dissected and
divided into cortex, hippocampus, olfactory bulb, and cer-
ebellum. These parts were then kept at 280C until use.
For enzyme-linked immunosorbent assay (ELISA) assays,
hippocampal tissues were homogenized in lysis buffer
consisting of radioimmunoprecipitation assay and 1-mM
ethylenediaminetetraacetic acid (EDTA) and prepared ac-
cording to the protocol from BetaMark ELISA Kit SIG-
38952 or 38954 (Covance). For protein extraction, tissues
were homogenized in lysis buffer consisting of 50-mM
Tris (pH 7.5), 150-mM NaCl, 1-mM EDTA (pH 8.0), 1-
mM phenylmethylsulfonyl fluoride, 1% Triton X-100, pro-
tease inhibitor cocktail (Sigma, St Louis, MO, USA), and
phosphatase inhibitor cocktail (Roche Applied Science, In-
dianapolis, IN, USA). Total protein concentration was
measured using the Bradford Reagent (Thermo Scientific/
Pierce Biotechnology, Rockford, IL, USA).
Ten micrograms of total protein lysate per sample were
resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis and transferred onto a nitrocellulose mem-
brane, and probed with antibodies against glyceraldehyde
3-phosphate dehydrogenase (1:2000, Abcam), mHDAC6
(1:2000, Abcam), human tau (1:2000, Abcam), acetylated
tubulin (1:1000, Cell Signaling), and pSer262 Tau (1:2000,
Millipore). Western blot analysis was performed with
infrared dye–conjugated secondary antibodies, IR700 and
IR800 (LI-COR Biosciences, Lincoln, NE, USA). Blots
were imaged and processed on an Odyssey Infrared Imaging
System.2.7. Drug administration and pharmacokinetic
measurements
Like many hydroxamic acid–based compounds, ACY-
738 demonstrates a relatively short half-life when injected
intraperitoneally (IP) in mice [8]. To avoid the repeated
stress of twice daily IP injections, we developed a rodent
chow–based formulation of the compound. The level of
ACY-738 in chow was based on extensive pharmacokinetic
studies performed in rats. When dosed orally at 10 mg/kg,
ACY-738 achieves a maximum plasma concentration of
212 ng/mL (79 nM) with a half-life of 2.2 hours. In cell-
based assays (data not shown), a concentration of between
10 and 100 nM induces a significant acetylation of a-tubulin
with little acetylation of histones, indicating that this con-
centration range is selective for HDAC6 over class I HDACs
(data not shown). Therefore, we calculated that the amount
of drug in the chow should be sufficient to deliver 10 mg/
kg ! 24/2.2 hours or 100 mg/kg. Calculating that mice
consume 4 g of chow per day, we formulated Harlan Teklad
diet 7012 to contain 0.625 mg of ACY-738 per gram of chow(4 g! 0.625 mg 5 2.5 mg/0.025 kg per mouse 5 100 mg/
kg). Mice were weighed weekly to monitor overt toxicity of
diet-based treatment of ACY-738. For PK analyses, ACY-
738 was measured in plasma and brain by liquid chromatog-
raphy/tandem mass spectrometry. Drugs were extracted
from brain and plasma by protein precipitation using
50: 50 acetonitrile:methanol and analyzed using a high per-
formance liquid chromatography/mass spectrometry
(HPLC/MS/MS) method using electrospray ionization in
positive mode as previously reported [28]. The lower limit
of quantification for all compounds was 3 ng/mL. PK param-
eters (concentrations, T1/2, concentration (AUC) AUCBrain/
AUCPlasma) were estimated by noncompartmental model us-
ing WinNonlin (Pharsight, Sunnyvale, CA, USA).
2.8. Enzyme-linked immunosorbent assays
Hippocampal tissue was isolated from 3- and 6-month-
old mice (early and late treatment groups, respectively)
and kept until 280C until use. Tissue was homogenized
in 1! tris buffered saline with protease and phosphatase in-
hibitors and EDTA. Homogenates were then spun at 4C at a
speed of 350,000! g using tabletop ultracentrifuge (Beck-
man Coulter). Supernatants were isolated and used at 1:2 di-
lutions for the assay. Plasma samples were isolated from
both groups using retro-orbital bleeds, as described previ-
ously, and were also diluted at 1:2 for the assay. Colorimetric
ELISA kits specific for Ab 1–40 (Covance) and 1–42 (Cova-
nce) were used to measure total amyloid in both brain and
plasma samples.
2.9. Immunohistochemistry
APP/PS1 and WT littermate mice (6-month-old) were
anesthetized with 5% isoflurane and euthanized using cervi-
cal dislocation. The brain was dissected and half was imme-
diately placed in 10% formalin for postfixation, whereas the
other half was snap-frozen and used for biochemical analysis
as described in Section 2.6. The samples were rinsed with
1! phosphate-buffered saline, transferred to one wash of
50% ethanol for 1 hour, then 70% ethanol overnight. The
samples were then embedded in paraffin. The samples
were then sectioned along the sagittal plane at 20-mm thick-
ness and directly mounted onto precleaned/coated slides.
The sections were stained with Ab antibody 1–42 (Invitro-
gen) after formic acid treatment. The sections were also
stained with Congo red to visualize plaque cores. Slides
were imaged usingMETA 510 ConfocalMicroscope (Zeiss).3. Results
3.1. ACY-738 treatment improves axonal transport rates in
early and late treatment groups
Both APP/PS1 mice and WT littermates were assigned
randomly to either treated or untreated groups for the course
of this study. In both early and late treatment groups, mice
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ACY-738 chow (treated) and weighed weekly to monitor
overt toxicity. Weight from treated and untreated APP/PS1
and WT mice are displayed in Supplementary Fig. 1A and
B. There are no significant differences in weight gain be-
tween treated and untreated groups.
In both groups, axonal transport measurements were con-
ducted using MEMRI as described previously [13]. In 3-
month-old mice, axonal transport deficits for APP/PS1
mice are 65% of WT mice. Treatment of WT mice had no
effect on axonal transport rates (Fig. 1A). After 21 days of
ACY-738 treatment, APP mice exhibited axonal transport
rates that were comparable to WT animals. In 6-month-old
mice, axonal transport deficits for APP-untreated mice are
38% of WT untreated mice (Fig. 1B). Treatment with
ACY-738 for 3 months significantly recovered axonal trans-
port deficits for APP/PS1 mice.Fig. 1. Axonal transport rates are improved in both early and late treat-
ment groups. Quantification of axonal transport rate is displayed for
mice treated for (A) 21 d before evaluation at the age of 3 mo for all
groups and (B) for mice treated for 90 days before evaluation at the
age of 6 months. WT untreated n 5 8 (early), 10 (late), APP untreated
n 5 6 (early), 11 (late), WT treated n 5 4 (early), n 5 5 (late), APP
treated, n 5 8 (early), n 5 9 (late). Two-way ANOVA was conducted
with multiple comparisons, *P , .05, **P , .01, ***P , .005. Abbrevi-
ations: WT, wild-type; APP, amyloid precursor protein; ANOVA, anal-
ysis of variance.3.2. ACY-738 is present at therapeutic levels in the brain
and plasma of APP/PS1 mice
ACY-738 levels were measured in plasma and cortical
samples from all treatment groups using HPLC (n 5 3 per
group). In the early group, untreated mice displayed ACY-
738 levels that were below quantifiable limits for both
plasma and brain samples. In cortical samples, treated
mice displayed an average of 16.07 (WT) and 17.93 nano-
grams of ACY-738 per gram of tissue (59 and 66 nM;
Fig. 2A). When examining the plasma drug levels, WT-
and APP-treated groups contained an average of 22 and
27.07 ng/mL of ACY-738, respectively (81 and 100 nM;
Fig. 2A). In the late-treatment group, all untreated mice dis-
played ACY-738 levels that were below quantifiable limits
for both plasma and brain samples. In cortical samples,
treated WT mice displayed an average of 17.80 ng/g (WT)
and 14.20 ng/g (APP) of ACY-738 per gram of tissue (66
and 52 nM; Fig. 2B). In the plasma, both WT- and APP-
treated groups contained an average of 40.35 and 50 ng/
mL of ACY-738, respectively (149 and 185 nM; Fig. 2B).
The higher levels of drug in the older animals likely repre-
sent a different rate of metabolism of the drug. ACY-738 is
rapidly converted from a hydroxamic acid to a carboxylic
acid, most likely through a glucuronide intermediate, by en-
zymes in the liver. The carboxylic acid has no HDAC inhib-
itory activity (data not shown).3.3. ACY-738 treatment elevates protein levels of
acetylated tubulin while lowering levels of
hyperphosphorylated tau protein
Cortical samples from treated and untreated APP/PS1
mice and WT littermates were isolated, and a Western blot
was used to measure protein levels of acetylated a-tubulin,
a-tubulin, GAPDH, human tau, and phosphorylated tau
Ser262. Untreated APP/PS1 mice displayed significantly
lower levels of acetylated tubulin when compared withWT mice, and these levels were significantly elevated after
an early treatment with ACY-738. A visual representation
of these Western blots and their quantification are displayed
in Fig. 3A. We also measured hyperphosphorylated tau
levels at Ser262 and normalized these levels to tau and
GAPDH as a loading control. Untreated APP/PS1 mice
display slightly elevated levels of hyperphosphorylated tau
at Ser262, which are normalized to WT levels after an early
treatment with ACY-738 chow. A representative Western
blot and their quantification are displayed in Fig. 3B. This
is similar to the reduction in phosphorylated tau seen with
a 0.5-mg/kg injection of ACY-738 [38].
3.4. ACY-738 treatment improves hyperactivity and fear-
associated contextual learning and memory
Only mice from the late-treatment groups were evalu-
ated using both an open field assay and short-term and
long-term contextual fear conditioning paradigms because
of no reported behavioral deficits ssin APP/PS1 mice at
age 3 months. APP/PS1-untreated mice traveled much
further (197.2 m) compared with WT-untreated mice
(94.21 m). There was no change in WT mice treated with
ACY-738 chow (101.6 m); although APP/PS1-treated
mice showed recovery back to WT levels (122 m) groups
(Fig. 4A). In the contextual fear conditioning assay,
Fig. 2. ACY-738 is present in the brain and plasma of treated mice in both early and late groups. Quantification of samples from plasma and brain tissue is
displayed (A) for the early treatment group and (B) for the late treatment group. n 5 3 for all groups, one-way ANOVA was performed for both early and
late treatment groups; significance is indicated for treated to untreated groups, *P, .05, **P, .01, ***P, .005. Abbreviations: ANOVA, analysis of variance;
WT, wild-type; APP, amyloid precursor protein.
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percent freezing compared with the WT-untreated group,
with an average of 21% and 30%, respectively (Fig. 4B).Fig. 3. A) Cortical brain tissue was collected from all treatment groups and proces
an anti-taupSer262 antibody (1:1000) tau 5 antibody (1:2000), acetylated tubulin
imaged using the LI-COR System (Odyssey) and B) quantified using ImageJ (NIH)
ANOVA, analysis of variance; WT, wild-type; APP, amyloid precursor protein.The results of a short-term (2 hours posttraining) recall
paradigm illustrate a significant recovery in contextual
fear–associated memory deficits, with the percent freezingsed for Western blots, n5 3 per group. Samples displayed were probed with
antibody (1:2000), a-tubulin antibody (1:5000), and GAPDH (1:2000) and
. One-way ANOVA test was conducted, *P, .05, **P, .01. Abbreviations:
Fig. 4. WTand APP/PS1 mice (male and female, 6–7 mo old) were treated with normal or ACY-738 chow for 90 d before testing using an open field assay for
30 min and contextual fear conditioning paradigm. Results are reported for total distance traveled in the open field (A) and as % freeze as an indication of fear-
associated memory recall. Graph displays preconditioned stimulus (pre-CS), short-term recall (2 h), and long-term recall (24 h) (B). Groups tested include WT
untreated (n5 20), APP/PS1 untreated (n5 13), WT treated (n5 13), and APP treated (n5 15). Two-way ANOVAwas conducted with multiple comparisons.
*P , .05, **P , .01. Abbreviations: WT, wild-type; APP/PS1, amyloid precursor protein/presenilin 1; ANOVA, analysis of variance.
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the APP/PS1-treated group (Fig. 4B). When mice were
placed in a long-term (24 hours posttraining) recall para-
digm, the deficit in learning and memory was even more
significant between the untreated groups, with percent
freezing of WT mice at 30% and APP mice at 15%. There
is a significant recovery of long-term recall, with 20% for
the WT-treated group and 25% for the APP-treated group
(Fig. 4B).3.5. ACY-738 treatment improves amyloid pathology in
APP-treated mice
We used an ELISA to quantify the levels of human Ab 1–
40 and 1–42 in all late-treatment groups in the cortex of both
treated and untreated mice. Both soluble and insoluble Ab 1–
42 levels were significantly elevated in APP-untreated mice
compared with WT, and ACY-738 treatment significantly
decreased the levels of insoluble Ab 1–42 (Fig. 5A). This
was also confirmed when calculating the Ab 42/40 ratios,
which indicated that the insoluble ratio was significantly
decreased in the treated APP mice (Fig. 5B). To confirm
the pathology visually, we stained brain slices from the
late-treatment cohort with an amyloid 1–42 antibody, which
revealed an average of seven plaques per slice in APP-
treated mice compared to one plaque per slice in APP-untreated mice. Representative images of APP untreated,
treated, and plaque histology are displayed in Fig. 6A. Plaque
staining quantification is indicated in Fig. 6B. Soluble amy-
loid puncta (neuritic plaque cores) were also imaged using
Congo red. Representative images are displayed in Fig. 6C.
Puncta quantification is indicated in Fig. 6D.4. Discussion
A reduction of fast axonal transport associated with
neurodegenerative disease has been well established. The
involvement of HDAC6 in this process has been demon-
strated in vitro [23,39]. Here, we demonstrate the role of
HDAC6 in fast axonal transport in vivo and link this effect
to behavioral consequences.
We evaluated the effectiveness of a novel, specific
HDAC6 inhibitor (ACY-738) in a preclinical proof-of-
concept study using APP/PS1 mice. From a close examina-
tion of previous literature, we constructed a model indicating
the role of HDAC6 and its interactions in healthy and
diseased neurons (Fig. 7). Specifically in the context of
drug development, class I HDAC inhibitors have been
used in humans primarily for cancer. This is due to the obser-
vation that when compared with class I inhibitors, class II
HDACs are downregulated in tumor samples. In addition,
the higher the expression of this class of HDACs, the
Fig. 5. Insoluble 1–42 levels are significantly reduced after ACY-738 treatment in the cortex. ELISA quantification of amyloid 1–42 (A) and the ratio of 42/40
are displayed in (B). Levels of both are significantly reduced after ACY-738 treatment and are displayed in picograms per milliliter. n5 5 per group, one-way
ANOVAwas performed with Turkey’s comparisons. *P, .05, **P, .01, ***P, .001. Abbreviations: ELISA, enzyme-linked immunosorbent assay; ANOVA,
analysis of variance; WT, wild-type; APP, amyloid precursor protein.
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has been the focus of cancer therapy with the challenge of
trying to limit off-target effects to class II HDACs. SomeFig. 6. Representative images from APP-untreated and APP-treated mice from th
cation of plaques is represented as plaque per slice (B). Representative images fro
plaque cores) is represented as puncta per slice (D). n 5 3 per group and t tests w
Abbreviation: APP, amyloid precursor protein.side effects that have been reported in humans include fa-
tigue, confusion, and mild hepatotoxicity [40]. However,
modulation of HDACs in general is always dose dependente late treatment group stained with an amyloid beta antibody (A). Quantifi-
m Congo red staining are displayed (C). Quantification of puncta (neuritic
ere performed between APP-treated and APP-untreated groups. *P , .05.
Fig. 7. A hypothetical model is displayed for microtubules in both normal and diseased states. Alterations in the diseased state include increased levels of
HDAC6, increases in amyloid, ROS levels, and posttranslational modifications to both tau and tubulin. Abbreviations: HDAC6, histone deacetylase 6; ROS,
reactive oxygen species.
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have not been tested in clinical trials.
Modulating HDAC6, a member of the class II family,
has shown promise in preclinical trials for neurodegener-
ative diseases. Specifically, HDAC6 is mainly cyto-
plasmic, and targets a-tubulin primarily. In mouse
models knocking out HDAC-6, mice are normal throughout
development. Because of the two catalytic domains present
in HDAC6, the off-target effects are limited [41]. The pri-
mary roles of HDAC6 are within the microtubule network
and in response to accumulation of misfolded proteins. Spe-
cifically, HDAC6 plays roles in autophagy and the induction
of heat shock proteins to assist with active transport to the
aggresome. There is also evidence of deacetylation of two
antioxidant enzymes known as peroxiredoxins. This allows
the promotion of neurite growth and protection against
oxidative stress. Finally, tau can play both an inhibitory
and enhancing role in HDAC6 within the microtubules
[42]. It is possible that this allows for acute and initial inhi-
bition by HDAC6 and then a modulation of autophagic pro-
cesses in the brain.
Some potential off-target effects of HDAC6 inhibitors is
the induction of apoptosis and T-cell immune response.
These can be circumvented with specific dose-dependent
regulation and selectivity within the tubulin deacetylation
catalytic domain of HDAC6 [43].
Recent evidence and studies involving other commer-
cially available HDAC6 inhibitors have been delivered
intravenously with a range of effects on amyloid and tau
pathology [23,24,28]. Particularly, tubastatin has beendemonstrated to have affects on tubulin acetylation in
the brain as well as interact with tau pathology in a
recent in vivo study [44]. However, none of the previous
studies have delivered HDAC6 inhibitors orally demon-
strating both functional axonal transport improvements
and changes in PTMs of tau pathology. Diet-based deliv-
ery is advantageous in that it easily translates to delivery
in the patient. We have shown that ACY-738 can reach
therapeutic levels in our organ of interest (brain) and sub-
mit that this is particularly advantageous for future work.
However, a limitation of this study is duplication of these
results in a tau model, which is also applicable to other
relevant forms of dementia and AD pathology within the
brain.
The role of axonal transport deficits as an early indicator of
neuronal damage as well as a link between both amyloid and
tau pathology have been established both in vitro and in vivo in
a number of models of neurodegenerative diseases [11,18,45].
However, this study is a comprehensive evaluation of a novel
pharmacologic compound demonstrating robust improvement
using MEMRI as an in vivo methodology in the APP/PS1
mouse model. Beyond preclinical models, axonal transport
has been measured ex vivo in a number of brain samples
from patients with AD, primarily by measuring the transport
rates of vital organelles such as mitochondria [46,47].
Although our methodology for measuring axonal transport
rates is not specific to organelle transport, the link between
the normalization of mitochondrial dynamics, increase in
motor protein function, and improved transport rate has been
previously established [8–10,47–49].
T. Majid et al. / Alzheimer’s & Dementia: Translational Research & Clinical Interventions 1 (2015) 170-181 179Our study also confirmed a number of relationships be-
tween PTMs of tau, tubulin, and HDAC6. Previous studies
have indicated that HDAC6 interacts with tau and is primarily
responsible for the regulation of acetylated tubulin
[19,21,50]; however, recent work indicates that some of
these interactions may be selectively inhibited. For
example, studies that have used tubastatin A and other
similar inhibitors have been met with limited success due to
the pharmacokinetics of these inhibitors as well as the
limited potency in the brain, whereas ACY-738 demonstrates
a highly specific and potent presence in brain tissue. Addi-
tionally, although the acetylation of tubulin is affected
when delivered to tau models [22,51], there are limited
effects on the amyloid clearance potential of these
inhibitors. Our study indicates that inhibiting HDAC6 using
ACY-738may be effective both at early and late stages of dis-
ease progression as well as help reduce some of the amyloid
levels in the brain. However, a limitation of the study is the
measurement of a single hyperphosphorylated tau epitope,
pSer262, which was chosen as the most relevant location
for HDAC6 to interact, based on previous literature. Other
epitopes (pSer202, pT149, and so forth) did not display sig-
nificant differences (data not shown), indicating HDAC6 in-
hibitionvia ACY-738may be preferential to pSer262 binding.
In addition to the extension of axonal transport character-
ization in this study, we also find that ACY-738 treatment ef-
fects hyperactivity, and fear-associated learning andmemory.
This is indicative of an improvement in some of the cognitive
processes and phenotypes just before the onset of amyloid pa-
thology in this mouse model. We interpret this modest in-
crease in associative fear conditioning to the nature of
variation in consumption of ACY-738 between groups. The
WT-treated mice display a 20% freezing rate and the
improvement is 25% for the APP-treated group, which could
be due to the nature of the variation in chow consumption and
acute plasma elevation level within the WT group. We find
theWTmice also to have slight elevations in oxidative stress,
which do not affect amyloid pathology but could account for
limited freezing. In addition, we observe a significant reduc-
tion in the soluble amyloid 42/40 ratio, often a clinically rele-
vant outcome used in patient studies. The insoluble ratio
remains unchanged in all groups, which may be due to the
lack of sensitivity of this particular ELISA with small
changes in insoluble Ab. The APP/PS1 model used in this
study has very few plaque deposits at age 6 months, and it
is possible the plaques that are visualized in this study are
not fully neuritic or insoluble until later in the progression
of the disease. However, we do observe a significant reduc-
tion in plaque load in the APP-treated groups, indicating
that it is possible to recover aggregated forms of Ab with
ACY-738 treatment. However, more studies must be
completed to know the effects of long-term treatment with
ACY-738 and its effect on aggresome formation to fully
elucidate this mechanism of improvements.
Our current work demonstrates that assessing axonal
transport rates using MEMRI can be used as both an earlyindicator of decline and an early output measure of improve-
ment and that this is not only reflected through short-term
behavioral improvements but also through PTMs of tau
and tubulin. Additionally, we find that amyloid pathology
is altered and improved in the hippocampus with an
extended treatment at a later stage of amyloid accumulation
in the APP/PS1 mouse model. Previous studies have indi-
cated that HDAC6may play a role in autophagosome forma-
tion [21], which warrant additional investigation after
treatment with ACY-738, along with specificity of this inhib-
itor to be effective acutely or over time in other models of
AD or related dementias.Acknowledgments
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1. Systematic Review: Our work investigates a novel,
potent, specific HDAC6 inhibitor developed by Ace-
tylon Pharmaceuticals in a preclinical proof of
concept study for Alzheimer’s disease (AD). Recent
studies have investigated conventional HDAC6 inhib-
itors such as tubacin and tubastatinAwith limited suc-
cess because of lack of blood-brain barrier penetration
and toxicity.
2. Interpretation: Our study builds on previous work in
AD models using manganese-enhanced magnetic
resonance imaging as a noninvasive, longitudinal
measurement of in vivo axonal transport using ge-
netic overexpression models. In addition to this, we
submit this study as the first to effectively demon-
strate the oral delivery of ACY-738 in a mouse model
of AD.
3. Future Directions: In the future, more investigation
into the mechanisms of uptake and consistency of re-
sults in other models of AD are necessary to move
this compound into clinical trials.
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